MedTrace Logo

CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL

NCT06064903 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-12-02

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety, to establish the recommended dose, and to evaluate the antitumor effect of CD7-CART01 in pediatric patients with relapsed or refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LL).

Conditions

  • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma

Interventions

BIOLOGICAL

CD7-CART01

A single IV infusion of CD7-CART01 on Day 0

Sponsors & Collaborators

  • Bambino Gesù Hospital and Research Institute

    lead OTHER

Principal Investigators

  • Franco Locatelli, MD, PhD · Director Department of Hematology/Oncology and Cell and Gene Therapy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-21
Primary Completion
2028-09-30
Completion
2040-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06064903 on ClinicalTrials.gov